Elicio Therapeutics, Inc. (ELTX)
(Delayed Data from NSDQ)
$4.85 USD
-0.05 (-1.02%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $4.78 -0.07 (-1.44%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ELTX 4.85 -0.05(-1.02%)
Will ELTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ELTX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ELTX
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today?
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Elicio Therapeutics Announces Proposed Public Offering
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P